Tiger team: a panel of human neutralizing mAbs targeting SARS-CoV-2 spike at multiple epitopes

  1. Tal Noy-Porat
  2. Efi Makdasi
  3. Ron Alcalay
  4. Adva Mechaly
  5. Yinon Levy
  6. Adi Bercovich-Kinori
  7. Ayelet Zauberman
  8. Hadas Tamir
  9. Yfat Yahalom-Ronen
  10. Ma’ayan Israeli
  11. Eyal Epstein
  12. Hagit Achdout
  13. Sharon Melamed
  14. Theodor Chitlaru
  15. Shay Weiss
  16. Eldar Peretz
  17. Osnat Rosen
  18. Nir Paran
  19. Shmuel Yitzhaki
  20. Shmuel C. Shapira
  21. Tomer Israely
  22. Ohad Mazor
  23. Ronit Rosenfeld
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

The novel highly transmissible human coronavirus SARS-CoV-2 is the causative agent of the COVID-19 pandemic. Thus far, there is no approved therapeutic drug, specifically targeting this emerging virus. Here we report the isolation and characterization of a panel of human neutralizing monoclonal antibodies targeting the SARS-CoV-2 receptor binding domain (RBD). These antibodies were selected from a phage display library constructed using peripheral circulatory lymphocytes collected from patients at the acute phase of the disease. These neutralizing antibodies are shown to recognize distinct epitopes on the viral spike RBD, therefore they represent a promising basis for the design of efficient combined post-exposure therapy for SARS-CoV-2 infection.

Related articles

Related articles are currently not available for this article.